Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12789664 | 0.87 | EPHX1 (0.60) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL22876809 | 0.81 | EPHX1 (0.40) | EPHX1CA2CA1 | |
| SCHEMBL12789674 | 0.81 | EPHX1 (0.55) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL7023194 | 0.78 | EPHX1 (0.69) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL25955799 | 0.77 | EPHX1 (0.52) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL17987909 | 0.76 | EPHX1 (0.50) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL20079220 | 0.76 | EPHX1 (0.50) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL14365951 | 0.76 | EPHX1 (0.46) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL606518 | 0.75 | EPHX1 (0.54) | EPHX1CA2CA1MEN1HTT | |
| SCHEMBL12206783 | 0.74 | EPHX1 (0.53) | EPHX1CA2CA1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | EPHX1 3571/4885CA2 565/4885CA1 3638/4885 |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | HRH4, CHRM5, CHRM1 | EPHX1 3571/4885CA2 565/4885CA1 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.